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In many infections, bacteria form surface-associated
communities known as biofilms that are substantially
more resistant to antibiotics than their planktonic
counterparts. Based on the design features of active
antibiofilm peptides, we made a series of related
12-amino acid L-, D- and retro-inverso derivatives.
Specific D-enantiomeric peptides were the most
potent at inhibiting biofilm development and eradi-
cating preformed biofilms of seven species of wild-
type and multiply antibiotic-resistant Gram-negative
pathogens.Moreover, these peptides showed strong
synergy with conventional antibiotics, reducing the
antibiotic concentrations required for complete bio-
film inhibition by up to 64-fold. As shown previously
for 1018, these D-amino acid peptides targeted the
intracellular stringent response signal (p)ppGpp.
The most potent peptides DJK-5 and DJK-6 pro-
tected invertebrates from lethal Pseudomonas aeru-
ginosa infections and were considerably more active
than a previously described L-amino acid peptide
1018. Thus, the protease-resistant peptides pro-
duced here were more effective both in vitro and
in vivo.
INTRODUCTION
Bacteria predominantly form biofilms when growing on surfaces
or at air-liquid interfaces (Costerton et al., 1999; O’Toole et al.,
2000; Kostakiot et al., 2013). Biofilms are encased in a protective
extracellular matrix that contains water, polysaccharides, pro-
teins, extracellular DNA, and lipids (Lo´pez et al., 2010). The tran-
sition from a planktonic to a biofilm lifestyle results in increased
resistance to exogenous stresses, including conventional anti-
microbial therapy and host defense mechanisms (de la Fuente-
Nu´n˜ez et al., 2013; O’Toole et al., 2000; Van Acker et al.,
2014). Therefore, biofilms are extremely difficult to eradicate
with currently available antimicrobial agents. Indeed, biofilms196 Chemistry & Biology 22, 196–205, February 19, 2015 ª2015 Elseplay an important role in the pathogenesis of numerous bacterial
species because of their ability to persist onmedical devices and
in the host (Costerton et al., 1999).
There is currently an urgent need to develop new antibacte-
rial agents to treat increasingly prevalent multidrug-resistant
bacteria (Boucher et al., 2009; Breidenstein et al., 2011). These
antibiotic-resistant bacteria are capable of forming biofilms
that are highly (adaptively) resistant to antibiotics, thus making
treatment of these infections even more difficult. Cationic
host defense peptides represent a potential alternative to
clinically available antibiotics (Fjell et al., 2011; Hancock and
Sahl, 2006). These peptides exhibit antimicrobial activity
(against free-swimming planktonic cells) and/or possess immu-
nomodulatory properties (de la Fuente-Nu´n˜ez et al., 2014b; Hil-
chie et al., 2013). In addition, it was shown that the human
peptide LL-37, despite very poor activity against free-swim-
ming (planktonic) cells (minimum inhibitory concentration
[MIC] >64 mg/ml), is active against Pseudomonas aeruginosa
biofilms at a concentration of one-sixteenth the MIC (Overhage
et al., 2008).
Recently, synthetic cationic peptides with antibiofilm activity
were identified and characterized (Amer et al., 2010; Dean
et al., 2011; de la Fuente-Nu´n˜ez et al., 2012, 2014a). Intriguingly,
these peptides seem superficially similar to the cationic antimi-
crobial peptides that are active against planktonic bacteria.
These similarities include being short (12–50 amino acids long)
and containing cationic amino acids (2–9 Arg or Lys residues)
and a high proportion of hydrophobic residues (50%). How-
ever, these activities can be clearly distinguished. Indeed, pep-
tides with good antibiofilm but little antiplanktonic cell activity,
and vice versa, have been demonstrated (de la Fuente-Nu´n˜ez
et al., 2012). Furthermore, these peptides were active against
Burkholderia cenocepacia biofilms, even although planktonic
B. cenocepacia are resistant to antimicrobial peptides. Recently,
a broad-spectrum antibiofilm peptide (peptide 1018) was shown
to act by binding to and triggering the degradation of the stress-
related second messenger nucleotides guanosine penta- and
tetraphosphate ((p)ppGpp) (de la Fuente-Nu´n˜ez et al., 2014a).
These unusual nucleotides play an important role in biofilm
development in many bacterial species (Aberg et al., 2006; Cha´-
vez de Paz et al., 2012; de la Fuente-Nu´n˜ez et al., 2014a; Sugi-
saki et al., 2013).vier Ltd All rights reserved
Table 1. Screen to Assess the Antibiofilm Activity of
D-Enantiomeric Peptides against P. aeruginosa (Pa) and
K. pneumoniae (Kp) Using the BioFlux Microfluidics System
Peptide
Name Type of Peptide
Sequences
(All Peptides
Amidated)
% Biofilm
Inhibition at
10 mg/ml
Pa Kp
L1018 normal VRLIVAVRIWRR 99 99
RI1018 retro-inverso RRWIRVAVILRV 95 5
L1012 normal IFWRRIVIVKKF 41 1
RI1012 retro-inverso FKKVIVIRRWFI 95 0
L1002 normal VQRWLIVWRIRK 7 0
RI1002 retro-inverso KRIRWVILWRQV 72 73
LJK1 normal VFLRRIRVIVIR 6 1
DJK1 D-enantiomer VFLRRIRVIVIR 85 87
RIJK1 retro-inverso RIVIVRIRRLFV 0 –
LJK2 normal VFWRRIRVWVIR 43 –
DJK2 D-enantiomer VFWRRIRVWVIR 87 –
RIJK2 retro-inverso RIVWVRIRRWFV 91 91
LJK3 normal VQLRAIRVRVIR 0 –
RIJK3 retro-inverso RIVRVRIARLQV 100 99
DJK3 D-enantiomer VQLRAIRVRVIR 45 –
LJK4 normal VQLRRIRVWVIR 12.7 0
RIJK4 retro-inverso RIVWVRIRRLQV 99.8 71
DJK4 D-enantiomer VQLRRIRVWVIR 99 99
LJK5 normal VQWRAIRVRVIR 0 –
RIJK5 retro-inverso RIVRVRAIRWQV 0 –
DJK5 D-enantiomer VQWRAIRVRVIR 99.7 99.8
LJK6 normal VQWRRIRVWVIR 69 0
RIJK6 retro-inverso RIVWVRIRRWQV 74 92
DJK6 D-enantiomer VQWRRIRVWVIR 98.4 98
Percentages represent the proportion of dead cells in the biofilm popula-
tion after treatment with 10 mg/ml of the different peptides at the begin-
ning of biofilm growth, as detailed in the Experimental Procedures
section. – denotes conditions that were not tested.One limiting feature of natural peptides is that they are
extremely susceptible to degradation by bacterial proteases
as well as host proteases that are present at sites of infection.
Recent work has indicated that a D-amino acid analog of
LL-37 was equally active against biofilms in vitro compared
with the L-amino acid variant but showed apparently superior
activity in a Galleria model (Dean et al., 2011). Therefore, here
we designed and made short D-enantiomeric, protease-resis-
tant peptides with broad-spectrum antibiofilm activity that
were shown to be up to 10-fold more potent than previously
identified peptides. The lead antibiofilm peptides DJK-5 and
DJK-6 exhibited activity in vivo, as they protected the nema-
tode Caenorhabditis elegans and the insect Galleria mellonella
from lethal P. aeruginosa infections. Both peptides synergized
with different classes of conventional antibiotics to prevent
biofilm formation and eradicate preexisting biofilms. These
peptides also acted by preventing the intracellular accumula-
tion of (p)ppGpp, which plays an important role in biofilm
development.Chemistry & Biology 22, 196RESULTS
D-Enantiomeric Peptide Screen
In most cases, both L- and D-antimicrobial peptides have been
shown to exhibit similar activity against free-swimming (plank-
tonic) bacteria (Epand and Vogel, 1999). This has been taken
to suggest that there is no receptor-mediated event involved in
the antimicrobial activity of these peptides. In contrast, recep-
tor-mediated events could potentially be involved when different
activities for L- and D-amino acid peptides of the same amino
acid sequence are observed, since e.g. in an a helix, there would
be opposite rotation of the backbone such that side chains
would appear in different positions in three-dimensional (3D)
space. Here, we tested the impact on antibiofilm activity of
making both retro (D-amino acid) and retro-inverso versions
(reversed sequence where all amino acids appear in the same
position in 3D space) of a series of peptides related to antibiofilm
peptide 1018, by using the high-throughput BioFlux apparatus
(Benoit et al., 2010). These peptides were designed based on
properties associated with 1018 and/or our most active antibio-
film peptides from preliminary screens, namely the use of only 9
of the 20 natural amino acids (V, R, L, I, A, W, F, K, Q), including 4
charged residues (most commonly R), 7 or 8 hydrophobic resi-
dues, and no more than 1 Q.
Intriguingly, and in strong contrast to planktonic antimicrobial
activity (Epand and Vogel, 1999), there was no obvious relation-
ship between peptide enantiomeric composition and antibiofilm
activity (Table 1). For example, while the retro-inverso version of
1018 retained antipseudomonal antibiofilm activity, it lost activity
versus Klebsiella biofilms. Conversely, RI-1002 was quite active,
but the L-version of this peptide was inactive. Overall the
D-amino acid versions of the peptides tended to be more active,
but there was substantial variability in activity between the D and
RI versions of several peptides. These data thus indicate that
there is no simple relationship between enantiomeric composi-
tion and activity. Nevertheless, because the D versions of pep-
tides tended to be more active and had the advantage of being
protease resistant, we decided to further evaluate these.
Six of themore active D-enantiomeric peptides were screened
for their relative ability to inhibit biofilm formation by the bacterial
pathogen P. aeruginosa strain PA14 (Table S1). Analogous to
previously reported antibiofilm peptides (e.g. Dean et al., 2011;
de la Fuente-Nu´n˜ez et al., 2012), these peptides exhibited
modest antimicrobial activity against planktonic cells (MIC), but
relatively strong antibiofilm activity (50% minimum biofilm inhib-
itory concentration [MBIC50]). These data revealed the impor-
tance of even small sequence changes. For example, DJK-2
and DJK-6 exhibited only a single change F2Q, but this led to
a 10-fold difference in MBIC50 (Table S1). Overall, peptides
DJK-5 and DJK-6 were identified as the most active antibiofilm
peptides obtained to date, since they had MBIC50 values versus
P. aeruginosa of 1 mg/ml and 0.5 mg/ml, respectively (Tables 2
and S1).
To confirm these results, we used the more sensitive flow cell
method and assessed the activity of peptides DJK-5 and DJK-6
against wild-type P. aeruginosa PA14 biofilms. Peptides were
added at 2.5 mg/ml, well below their MICs of 16 mg/ml, to the
flow-through medium in one of two ways: (1) inhibition studies,
in which peptides were added at the beginning of biofilm growth–205, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 197
Figure 1. D-Enantiomeric Peptides Com-
pletely Prevented Biofilm Formation and
Eradicated P. aeruginosa Biofilms
Sub-MIC concentrations (2.5 mg/ml) of peptides
DJK-5 and DJK-6 were used. Inhibition of biofilm
development was tested by immediately adding
peptide into the flow-through medium of the flow
cell apparatus and then monitoring biofilm forma-
tion for 3 days. Eradication conditions involved
waiting 2 days before addition of either peptide into
the flow-through medium. After 3 days, bacteria
were stained green with the all bacteria stain
Syto-9 and red with the dead bacteria stain pro-
pidium iodide (merge shows as yellow to red) prior
to confocal imaging. Each panel shows re-
constructions from the top in the large panel and
sides in the right and bottom panels (xy, yz, and xz
dimensions).and during the subsequent 3 days of the experiment; and (2)
eradication studies, whereby peptide was first added after
2 days of biofilm formation when the biofilm structure was
already evident. These studies showed that the peptides
DJK-5 and DJK-6 were able to prevent biofilm formation in inhi-
bition studies (Figure 1, center panels), as well as disperse and
eradicate bacteria in wild-type P. aeruginosa PA14 mature bio-
films (Figure 1, right panels).
D-Enantiomeric Peptides Exhibited Broad-Spectrum
Antibiofilm Activity
The L-amino-acid-containing peptide 1018 was previously
shown to have broad-spectrum activity versus Gram-negative
bacteria (de la Fuente-Nu´n˜ez et al., 2014a). To see if this was
also the case for D-enantiomeric peptides, we determined their
spectrum of activity. Both peptides prevented biofilm growth in
a wide range of bacteria at levels below their MICs for planktonic
cells (Table 2). DJK-5 inhibited biofilms at concentrations
ranging from 0.8 mg/ml to 4 mg/ml, while DJK-6 was most effec-
tive against the wild-type P. aeruginosa strain PA14 (0.5 mg/ml)
and showed lower activity against enterohemorrhagic Escheri-
chia coli isolate 0157 (8 mg/ml) (Table 2). As expected, these pep-
tides did not affect the planktonic growth of a clinical isolate of
B. cenocepacia, known to be completely resistant to antimicro-
bial peptides (MIC > 256 mg/ml for DJK-5 andMIC > 64 mg/ml for
DJK-6) but inhibited biofilms of this multidrug-resistant strain at
only 0.4 mg/ml and 2 mg/ml, respectively (Table S2). The
enhanced antibiofilm activity of these peptides occurred for a
broad range (7 different species and 30 strains) of wild-
type and multidrug-resistant pathogens, and especially all
Gram-negative members of the so-called ESKAPE pathogens
(Table S2).198 Chemistry & Biology 22, 196–205, February 19, 2015 ª2015 Elsevier Ltd All rights reservD-Enantiomeric Peptides Protected
C. elegans and G. mellonella from
Lethal P. aeruginosa Infections
To test for the ability of peptides to protect
against infections, we utilized two nonver-
tebrate models of P. aeruginosa infections
(Brackman et al., 2011; Cooper et al.,
2009; Edwards and Kjellerup, 2012; Stier-nagle, 2006). The C. elegans nematode model used here has
been shown to consistently develop biofilm infections (Brack-
man et al., 2011; Edwards and Kjellerup, 2012). Furthermore,
Dean et al. (2011) argued that protection in the Galleria larvae
model reflected antibiofilm rather than antibiotic activity versus
planktonic bacteria. Consistent with this concept, the tested
peptides had very weak MICs of 16–64 mg/ml versus planktonic
P. aeruginosa. The peptides tested included the optimized
D-enantiomeric peptides DJK-5 and DJK-6, as well as the previ-
ously described 1018 (de la Fuente-Nu´n˜ez et al., 2014a) and its
D-analog RI-1018.
Untreated controls infected with P. aeruginosa PAO1 demon-
strated 100%death after 48 hr in both infection models (Table 3).
After 24 hr of infection, each of the peptides significantly (p <
0.001) protected C. elegans against lethal P. aeruginosa infec-
tions, with DJK-5 and DJK-6 giving nearly complete protection
(Table 3). After 48 hr of infection, significant protection (p <
0.001) was observed only for animals treated with peptides
DJK-5 and DJK-6, while mortality was close to 100% (and not
significantly different from the peptide untreated control group)
for RI-1018 and 1018 (Table 3). The peptides by themselves
did not display any toxic activity againstC. elegans, since no sig-
nificant differences in survival were observed after 24 hr and
48 hr in uninfected C. elegans nematodes treated with peptides
compared with untreated animals (Table 3).
Using the G. mellonella infection model, no protective effect
was observed after 24 hr with peptide 1018, a moderate but sig-
nificant protective effect was observed for its D-analog RI-1018
as well as DJK-6, and a strong and significant protective effect
was conferred by DJK-5 (Table 3). After 48 hr, RI-1018 and
particularly peptides DJK-5 and DJK-6 resulted in significantly
increased survival (18%–42% survival; p < 0.001), whileed
Table 2. Antimicrobial (MIC), Broad-Spectrum Antibiofilm (MBIC50) Activities, and Synergistic Interactions between D-Enantiomeric
Peptides and Conventional Antibiotics
Strains
MIC
(mg/ml)
MBIC50
(mg/ml)
FIC
Fold Decrease in Antibiotic
Concentration
CTZ CIP IMI TOB CTZ CIP IMI TOB
DJK-5
P. aeruginosa 16 1 0.5 0.14 0.5 0.5 8 16 4 2
E. coli 0157 1.6 0.8 0.54 1 1 0.56 2 16 64 16
A. baumannii 8 4 0.75 1 0.75 0.56 2 1 2 16
K. pneumoniae 3.2 1.6 0.89 0.75 1 0.75 16 2 64 4
S. enterica 3.2 0.8 0.75 0.56 1 1.03 4 2 2 32
DJK-6
P. aeruginosa 16 0.5 0.48 0.46 0.92 1.13 16 4 2 1
E. coli 0157 16 8 0.35 0.5 0.67 0.5 16 32 2 4
A. baumannii 8 2 0.5 0.53 0.46 0.75 16 16 4 64
K. pneumoniae 4 2 1 0.75 0.75 0.63 2 4 4 4
S. enterica 4 1 1 0.56 0.63 0.75 2 16 4 4
MIC refers to the concentration of peptide that resulted in 100% inhibition of planktonic growth. MBIC50 corresponds to the peptide concentration that
results in 50% biofilm inhibition. To test for synergy, checkerboard titrations were performed to assess synergistic interactions between D-enantio-
meric peptides DJK-5 (A) and DJK-6 (B) and conventional antibiotics to prevent biofilm formation. The result was expressed as the FIC; the FIC values
indicating synergy (FIC < 0.5) or near synergy (FIC < 0.56) shown in bold. An FIC index of 0.5 is considered to indicate good synergy (representing the
equivalent of a 4-fold decrease in the MBIC of each compound when used in combination) and an FIC index of 1.0 represents additive activity (a 2-fold
decrease in the MBIC of each compound in combination). In most cases, peptides when combined with antibiotics reduced the antibiotic MBIC, here
depicted as fold decrease in antibiotic concentration at the FIC. CIP, ciprofloxacin; CTZ, ceftazidime; IMI, imipenem; TOB, tobramycin.complete killing was observed in the control group (Table 3).
Thus, in this model, although 1018 and its retro-inverso analog
RI-1018, after folding into an a helix, would have all amino acids
positioned in the same place in 3D space and had equivalent
antibiofilm activity versus P. aeruginosa (Table 1), only the latter
was protective, indicating an advantage for the protease-resis-
tant variant.
Broad-Spectrum Synergistic Interactions between
D-Enantiomeric Peptides and Conventional Antibiotics
to Treat Biofilms
Previous studies showed that antibiofilm peptide 1018 demon-
strated synergy with conventional antibiotics (Reffuveille et al.,
2014). To test whether this was still true for the more active pep-
tides, we adapted the checkerboard methodology (Reffuveille
et al., 2014) that is widely used to determine interactions be-
tween antibacterial compounds. The results obtained when pep-
tides DJK-5 and DJK-6 were combined with four of the most
commonly used antibiotics in human medicine (ceftazidime, imi-
penem, ciprofloxacin, or tobramycin) are shown in Table 2. In all
cases, we observed either synergy (fractional inhibitory concen-
tration [FIC] of <0.5, indicating that the MBIC of each compound
in combination was decreased by at least 4-fold compared with
the compounds used alone), near synergy (FIC < 0.56), or addi-
tive interactions (FIC = 0.5–1) (Table 2). Overall, 42.5% of the
combinations showed synergy or near synergy. Interestingly, in
95% of assessments, these peptides led to a substantial
decrease in the concentration of antibiotic required for antibio-
film activity, compared with antibiotic alone, with a 2- to 64-
fold drop in antibiotic concentration in combination (Table 2).
These results were confirmed using the flow cell assay at the
concentrations of peptide and antibiotic giving the lowest FIC,Chemistry & Biology 22, 196in checkerboard assays, against each tested bacterial species
(shown in Table 2). For example, the lowest FIC value obtained
for P. aeruginosa PA14was 0.14, corresponding to the combina-
tion 0.1 mg/ml of DJK-5 with 0.04 mg/ml of ciprofloxacin (Table 2).
Flow cell experiments confirmed these results, since this combi-
nation led to complete biofilm inhibition (Figure 2A). For all other
species tested, complete or nearly complete biofilm prevention
was observed at the concentrations giving the lowest FIC for
each peptide plus antibiotic combination, with only a few individ-
ual cells (some red-stained with the dead bacteria stain propi-
dium iodide) remaining attached to the surface of the flow cell
chambers (Figures 2A and 2B).
Similar results were observed using these combinations to
eradicate 2-day-old biofilms (Figure 3). For example, peptide
DJK-5, when combined with the antibiotics tobramycin, ceftazi-
dime, or ciprofloxacin, led to eradication of Acinetobacter bau-
mannii, Salmonella enterica, and Klebsiella pneumoniae mature
biofilms, respectively (Figure 3A). On the other hand, the combi-
nation of DJK-5 with ciprofloxacin versus P. aeruginosa PA14
caused much more limited dispersal but triggered cell death in
remaining cells (Figure 3A). In contrast, the combination of
DJK5 and ceftazidime versus E. coli was not synergistic in erad-
ication studies (Figure 3A). Combinations of DJK-6 with any of
the antibiotics tested led to disruption of preformed biofilms in
all cases (Figure 3B), with at most only a few cells remaining
attached to the surface of the flow cell chambers.
Mechanism of Action
Recently, the antibiofilm peptide 1018 was shown to bind to and
promote degradation of the signal for biofilm formation and
maintenance, (p)ppGpp (de la Fuente-Nu´n˜ez et al., 2014a).
Here, we performed selected experiments to demonstrate that–205, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 199
Table 3. In Vivo Antibiofilm Activity of D-Enantiomeric Peptides:
C. elegans and G. mellonella Biofilm Survival Assays
Peptide
C. elegans Survival (%)
24 hr 48 hr Post Infection
No
Infection
P. aeruginosa
PAO1
No
Infection
P. aeruginosa
PAO1
None 100 ± 0 61 ± 21 95 ± 4 1 ± 2
RI1018 99 ± 1 83 ± 13* 81 ± 23 4 ± 6
1018 97 ± 4 91 ± 12* 88 ± 9 1 ± 3
DJK5 99 ± 2 99 ± 2* 99 ± 2 96 ± 4*
DJK6 99 ± 2 99 ± 2* 97 ± 4 90 ± 5*
G. mellonella Survival (%)
CTRL 100 ± 0 13 ± 11 100 ± 0 0 ± 0
RI1018 90 ± 14 50 ± 8* 80 ± 10 18 ± 7*
1018 90 ± 14 27 ± 11 90 ± 14 3 ± 5
DJK5 100 ± 0 90 ± 6* 100 ± 0 42 ± 7*
DJK6 100 ± 0 50 ± 8* 100 ± 0 30 ± 6*
Percent survival of infected C. elegans and G. mellonella (average ± the
SD) after treatment with peptides D-enantiomeric peptides RI-1018
(and its L-version 1018), DJK-5 and DJK-6 and P. aeruginosa strain
PAO1. The results are expressed as the percent survival after both
24 hr and 48 hr of infection and peptide treatment. Statistical significance
comparing peptide-treated groups to untreated was determined.
*Survival significantly different from untreated control (p < 0.001).the more potent D-enantiomeric peptides, DJK-5 and DJK-6,
operated through the same mechanism. Thus, overproduction
of the potential target (p)ppGpp by treatment of P. aeruginosa
with 80 mM of serine hydroxamate (SHX) (Tosa and Pizer,
1971; Raskin et al., 2007) led to reduced susceptibility of
P. aeruginosa biofilms to peptide action (Figure S1). To examine
the fate of (p)ppGpp upon peptide treatment, we treated plank-
tonic cells with 500 mM SHX to enable them to accumulate
(p)ppGpp (Nguyen et al., 2011). Direct measurement of the
cellular levels of (p)ppGpp by thin-layer chromatography (TLC)
revealed that treatment with 1 mg/ml of peptides DJK-5 and
DJK-6 resulted in the complete loss of (p)ppGpp from
P. aeruginosa cells (Figure 4A). Treatment with 0.5 mg/ml of
RI-1018 also led to the absence of (p)ppGpp accumulation,
whereas the enantiomeric L-form equivalent 1018 required
5 mg/ml to achieve similar activity (Figure 4B). In addition, peptide
DJK-6 appeared to be more effective at enhancing degradation
of preaccumulated (p)ppGpp compared with its retro-inverso
version RI-JK6, and peptide RI-1018 (Figure 4C). Treatment
with RI-JK6 and DJK-6 degraded most of the pppGpp but not
the ppGpp nucleotide pool within 10 min (Figure 4C). After
20 min, however, both RI-JK6 and DJK-6 led to almost complete
disappearance of ppGpp and pppGpp (Figure 4C).
DISCUSSION
Multidrug-resistant Gram-negative pathogens are becoming
increasingly prevalent, including members of the ESKAPE path-
ogens, E. coli/Enterobacter, Pseudomonas, Klebsiella, and Aci-
netobacter, for which no fundamentally new drugs are under
development in the antibiotic pipeline (Boucher et al., 2009;200 Chemistry & Biology 22, 196–205, February 19, 2015 ª2015 ElsePayne et al., 2007). An additional concern is adaptive resistance,
whereby the growth state of the organism leads to nonmutational
high-level resistance to most currently available antibiotics (de la
Fuente-Nu´n˜ez et al., 2013). For example, biofilm growth leads to
multidrug-adaptive resistance (up to 10- to 1000-fold increased
resistance compared with planktonic bacteria) and is associated
with at least 65% of all human clinical infections (Kostakiot et al.,
2013). Moreover, there are currently no specific treatments for
biofilm-related infections.
Bacterial resistance strategies to antimicrobial peptides that
include enzymatic degradation of L-enantiomeric peptides
have been described previously, while host proteases can also
degrade such peptides during therapy (Fjell et al., 2011). Here,
we overcame these limitations, by designing D-enantiomeric
peptides, which cannot be recognized by bacterial or host pro-
teases that abound during infections and can cleave peptides
composed entirely of L-amino acids (Sieprawska-Lupa et al.,
2004).We then characterized the antibiofilm activities of D-enan-
tiomeric peptides against a range of Gram-negative bacterial
species, including multidrug-resistant strains (Table S2). Our
data demonstrated that the best peptides share many of the
features of L-amino acid peptides, but appeared to be superior
to previously described peptides, particularly in invertebrate
animal protection models. For example the broad-spectrum
peptide 1018 showed weak to no activity in two nonvertebrate
models. Conversely, the retro-inverso analog RI-1018 was
more active in both models. However, the most effective
peptides were the optimized D-enantiomeric peptides DJK-5
and DJK-6, which protected C. elegans nematodes and
G. mellonella larvae against lethal Pseudomonas infections.
Importantly, the C. elegans model used here is an established
biofilm infection model (Brackman et al., 2011; Edwards and
Kjellerup, 2012) and, together with the weak activity of these
peptides versus planktonic cells, is consistent with the D-enan-
tiomeric peptides having antibiofilm activity in vivo. This is also
true for the Galleria model that was suggested by Dean et al.
(2011) to demonstrate the antibiofilm activity of D-LL-37 in vivo,
although the level of protection by that peptide was substantially
lower than that presented here. Thus, it can be concluded that
D-enantiomeric peptides offer real advantages with regard to
activity in animal models where proteases abound.
Intriguingly, despite examining the activity of more than 100
L-amino-acid-containing peptides to date, 1018 appears to be
the most active. Nevertheless, the two most active D-peptides
described here, DJK-5 and DJK-6, were by and large consider-
ably more active. This likely reflects their resistance to proteases
encountered in the process of action on bacteria and possibly
also the increased ability of D-peptides to stimulate degradation
or prevent accumulation of (p)ppGpp (Figure 4B). Unlike some
antimicrobial peptides that appear to be able to act on mem-
branes or membrane-associated processes, antibiofilm pep-
tides that target (p)ppGpp must be able to translocate into cells
andwould thus be especially susceptible to intracellular or mem-
brane-bound proteases. In this regard, it is important to note that
amphipathic cationic peptides, like those described here, have
the characteristics of cell-penetrating peptides and can freely
translocate across membranes (Fjell et al., 2011). The overall ac-
tivity of these D-enantiomeric peptides is thus likely to reflect
their relative ability to be taken up into cells (i.e. ability to crossvier Ltd All rights reserved
Figure 2. D-Enantiomer Peptides DJK-5 and
DJK-6 Exhibited Antibiofilm Activity in Flow
Cells and Synergized with Conventional
Antibiotics in Preventing Biofilm Formation
by Different Bacterial Species
Subinhibitory concentrations of peptides DJK-5 (A)
and DJK-6 (B) in combination with antibiotics
prevented biofilm development of Gram-negative
bacteria. Inhibition of biofilm development was
tested by immediately (at the beginning of biofilm
growth at day 0) adding peptide plus antibiotic into
the flow-throughmedium of the flow cell apparatus
and then monitoring biofilm formation for 3 days.
After 3 days, bacteria were stained green with the
all bacteria stain Syto-9 and red with the dead
bacteria stain propidium iodide (merge shows as
yellow to red) prior to confocal imaging. Each panel
shows reconstructions from the top in the large
panel and sides in the right and bottom panels (xy,
yz, and xz dimensions). The top FIC combinations
of peptide + antibiotic (determined in checker-
board assays) were used.both the outer and cytoplasmic membrane), as well as their rela-
tive affinity for their target (p)ppGpp, which we have assessed
here for some peptides (Figure 4). Given the lack of a suitable
translocation assay into cells for any cationic peptide, to assess
the combined effects of translocation and affinity, we have
measured cellular (p)ppGpp nucleotide pools in TLC assays in
the absence and presence of different concentrations of pep-
tides (Figure 4). The structure-activity relationships are likely
very complex, as also observed for antimicrobial peptides where
dozens of physicochemical properties influenced activity,
including inductive properties that reflected 3D structure (Cher-Chemistry & Biology 22, 196–205, February 19, 2015kasov et al., 2009). For example, although
RI-JK1 and RI-JK5 differed from RI-JK6
by only two and three amino acids,
respectively, the former were inactive,
while the latter was very active (Table 1).
Similarly, a single amino acid substitution
Q2F in DJK-2 compared with DJK-6 led to
a 10-fold difference in MBIC50 (Table S1).
There were no apparent major differ-
ences in the properties of D-enantiomer
peptides assessed in vitro when com-
pared with L-enantiomers. Thus, antibio-
film activities were often superior to
activity versus planktonic cells, synergy
was often observed with antibiotics, and
the previously described target was still
evidently the same (de la Fuente-Nu´n˜ez
et al., 2014a). Previous reports showed
that, at the concentrations used in syn-
ergy studies, peptide treatment causes
biofilm dispersion (de la Fuente-Nu´n˜ez
et al., 2014a; Reffuveille et al., 2014) and
that the antibiotic susceptibility of these
dispersed cells was similar to that of
planktonic cells used in MIC assays
(Reffuveille et al., 2014). Therefore, wepropose that synergy reflects, at least in part, peptide-mediated
bacterial dispersal frombiofilms, increasing their susceptibility to
antibiotics.
The data favored a mechanism similar to that observed for
peptide 1018 (de la Fuente-Nu´n˜ez et al., 2014a), whereby pep-
tides DJK-5 and DJK-6 inhibited biofilm formation and sup-
pressed mature biofilms by entering cells and subsequently
targeting and causing the degradation of the intracellular nucle-
otides (p)ppGpp, which are important for the formation and
maintenance of biofilms. Furthermore, we have shown here
that the D-peptide RI-1018 was more potent at stimulatingª2015 Elsevier Ltd All rights reserved 201
Figure 3. Synergistic Interactions of D-Enantiomer Peptides DJK-5 and DJK-6 with Different Classes of Antibiotics in Treating Mature
Biofilms
Bacteria were grown in flow cells and treated at day 2 of biofilm formation with peptide, antibiotic, or the combination of both. The top FIC combinations of
peptide + antibiotic (determined in checkerboard assays) were used (as in Figure 2). In some cases, at the concentrations selected, the activity of the peptides led
to complete eradication of the flow cell biofilms. Thus, we decreased the levels of peptide used, which lowered the FIC values (see on the right hand side of panels)
compared with the checkerboard assay results shown in Table 2. Specifically, in (A) 0.8 mg/ml of DJK-5 (instead of 6.4 mg/ml) was used in combination with
tobramycin versus A. baumannii. In (B), 0.5 mg/ml of DJK-6 was used instead of 2 mg/ml combined with imipenem versus A. baumannii, 1 mg/ml of DJK-6
(as opposed to 2 mg/ml) was used in conjunction with ciprofloxacin versus S. enterica, and 0.5 mg/ml of DJK-6, instead of 2 mg/ml, was used in combination with
tobramycin versus K. pneumoniae. After 3 days, bacteria were stained green with the all bacteria stain Syto-9 and red with the dead bacteria stain propidium
iodide (merge shows as yellow to red) prior to confocal imaging. Each panel shows reconstructions from the top in the large panel and sides in the right and
bottom panels (xy, yz, and xz dimensions).degradation and/or preventing accumulation of (p)ppGpp in
P. aeruginosa comparedwith its L-formpeptide 1018 (Figure 4B).
D-peptides were also capable of promoting degradation of pre-
formed (p)ppGpp, as treatment with RI-JK6 andDJK-6 for 10min
substantially eliminated pppGpp, and after 20 min led to almost
the complete disappearance of both ppGpp and pppGpp nucle-
otide pools (Figure 4C). This represents increased activity
compared with the results obtained with L-1018, which did not
substantially decrease the (p)ppGpp pool after 10 min, and
was only able to lead to complete degradation of preformed
(p)ppGpp after 30 min of treatment (de la Fuente-Nu´n˜ez et al.,
2014a). Furthermore, we found that within the first 10 min of
treatment, the D-peptides, particularly RI-JK6 and DJK-6, led
to degradation of pppGpp but not ppGpp, which took twice as
long to disappear (Figure 4C). Thus, either the peptide interacts
more strongly with pppGpp to promote degradation (which is
possible since it is more highly negatively charged than ppGpp)
or first promotes the transition from pppGpp to ppGpp. Interest-
ingly, although another second messenger guanidine nucleotide
cyclic-di-guanosine monophosphate (cyclic-di-GMP) influences
the switch between planktonic and biofilm lifestyles (Hengge,202 Chemistry & Biology 22, 196–205, February 19, 2015 ª2015 Else2009; Ro¨mling et al., 2013), we have no direct evidence that it
is involved in the events described here, and it is noteworthy
that there was no obvious change in guanosine triphosphate
pools that can affect cyclic-di-GMP concentrations. Nor was
there any obvious influence of a specific growth condition, since
collectively we observed the biofilm inhibitory effects of peptides
in both nutrient and minimal medium.
Overall, in addition to protease resistance, which appears to
be an asset, the D-enantiomeric peptides retain two very potent
activities for countering drug resistance. First, they kill bacteria
growing as biofilms, which are known to be associated with
more than two-thirds of all infections in humans, and demon-
strate high adaptive resistance to multiple classes of antibiotics.
Second, the peptides showed synergy or additive effects with
highly utilized conventional antibiotics, rendering biofilms more
susceptible to these agents. Thus, the combination of D-enantio-
meric peptides with antibiotics enhanced the activity of antibi-
otics to target bacterial biofilms, both at the initial stages of
growth and in their mature state. The in vivo protective activity
of these peptides against otherwise lethal P. aeruginosa infec-
tions demonstrates the stand-alone potential of these peptides.vier Ltd All rights reserved
Figure 4. D-Enantiomeric Peptides Pre-
vented (p)ppGpp Accumulation and Led to
Disappearance of (p)ppGpp In Vivo
(A) Antibiofilm peptides DJK-5 and DJK-6 at 1 mg/ml
led to the absence of (p)ppGpp accumulation as
revealed by TLC separation of guanine nucleotides
extracted from intact cells as described in Experi-
mental Procedures.
(B) D-Enantiomeric peptides RI-1018 and DJK-5 led
to complete disappearance of (p)ppGpp more
potently than L-peptide 1018.
(C) D-Enantiomeric peptide DJK-6 exhibited
increased ability to trigger the degradation of pre-
formed (p)ppGpp compared with RI-1018 and RI-
JK6. 20 mg/ml of each of the three peptides was
used.Future studies will focus on the synergistic interactions of pep-
tides, in combination with antibiotics, in different animal models.
SIGNIFICANCE
There are relatively few novel compounds or strategies under
developmentorentering theclinic to treatmultidrug-resistant
Gram-negative bacterial pathogens, especially when they
become evenmore resistant growing as biofilms (the growth
state of bacteria in two-thirds of infections). Investigations of
the antibiofilmactivities of a seriesof related 12-mer peptides
comprising either L-amino acids or D-amino acids indicated
that the latter generally had better in vitro activities. The
best D-enantiomeric peptides had broad-spectrum activity
in vitro and were able to confer protection in two nonverte-
brate models against lethal infections caused by P. aerugi-
nosa, thus demonstrating their potential in vivo. As observed
for other L-enantiomeric peptides, the observed antibiofilm
activities were often superior to activity versus planktonic
cells, and synergy was often observed with antibiotics. In
addition, the peptides targeted the stringent response nucle-
otides (p)ppGpp, which play an important role in biofilm
formation. Thus, the D-enantiomeric antibiofilm peptides
described herehave thepotential tobeused innovel adjuvant
therapies that might be effective in combination with antibi-
otics against biofilms formed by antibiotic-resistant bacteria.
EXPERIMENTAL PROCEDURES
Bacterial Strains
Strains utilized included wild-type strains of P. aeruginosa PA01 and
PA14, B. cenocepacia isolate 4813 (isolate from a patient with cysticChemistry & Biology 22, 196–205, February 19, 201fibrosis attending Vancouver Children’s Hospital),
E. coli 0157, K. pneumoniae ATTC 13883
(a colistin-heteroresistant reference strain from
American Type Culture Collection, Rockville, MD),
multidrug-resistant A. baumannii SENTRY C8
(a polymyxin B-resistant blood clinical isolate
from the United States obtained through the
SENTRY surveillance system), and S. enterica
serovar Typhimurium isolate 14028S were used. A
complete list of the strains tested in this study is
provided in Table S2. The growth conditions ofthese strains were generally as described previously (de la Fuente-Nu´n˜ez
et al., 2014a).
Peptide Synthesis
All D-enantiomeric peptides were synthesized by CPC Scientific using solid-
phase 9-fluorenylmethoxy carbonyl (Fmoc) chemistry and purified to 95%
using reverse-phase high-performance liquid chromatography. Correct pep-
tide mass was confirmed by mass spectrometry.
BioFlux Microfluidic Studies
BioFlux studies were performed as previously described (Benoit et al., 2010)
using a K. pneumoniae strain LM21 gfp (Balestrino et al., 2005) and a
P. aeruginosa gfp strain. For use in biofilm experiments, Lysogeny broth (LB)
cultures were grown to an optical density at 620 nm of 0.5 and seeded into
BioFlux 48-well flow-channel plates (Fluxion P/N 950-0010) for 5 s and incu-
bated with no flow for 45 min to allow bacterial attachment. 1 ml of diluted
synthetic peptide suspension was added to the inlet wells at the beginning
of biofilm growth. Shear flow was applied at 5 dyn/cm2 overnight. Biofilm
development was periodically checked via brightfield microscopy, and at
the end of the study, residual cells were detected by GFP fluorescence and
dead cells were detected using the fluorescent dead-cell stain propidium io-
dide using a Nikon Eclipse Ti inverted epifluorescence scope and associated
digital camera for biofilm visualization and micrograph collection. Quantitative
green (total bacteria) and red (dead bacteria) fluorescence intensity data were
extracted from micrographs using Montage Offline (Fluxion 940-0004).
MIC, MBIC50 Assays
The broth microdilution method with minor modifications for cationic peptides
(Wiegand et al., 2008) was used for measuring the MIC of all D-enantiomeric
peptides used. MBICs leading to 50% decrease in adherent (biofilm) growth
(MBIC50) were obtained using 96-well plate assays and crystal violet staining
of adherent biofilms as previously described (de la Fuente-Nu´n˜ez et al., 2012).
Biofilm Growth Conditions in Checkerboard Assays
The medium used was generally LB, except for S. enterica serovar Typhimu-
rium isolate 14028S, which was grown in BM2 minimal medium (62 mM5 ª2015 Elsevier Ltd All rights reserved 203
potassium phosphate buffer [pH 7.0], 7 mM [(NH4)2SO4, 2 mMMgSO4, 10 mM
FeSO4]) containing 0.5% casamino acids and 0.4% (wt/vol) glucose as a car-
bon source, and K. pneumoniae, which was grown in Todd Hewitt broth
medium containing 0.4% yeast extract. Bacteria were grown for 24 hr in all
cases, except for K. pneumoniae, which was allowed to grow for 48 hr. In
checkerboard assays, the MBIC values represented the concentration (or
combinations of concentrations when using peptides in combination with anti-
biotic) at which 100% biofilm inhibition was observed. The result was ex-
pressed as the FIC index, calculated as follows: FIC = [A]/MBICA + [B]/MBICB,
where MBICA andMBICB are the MBICs of peptides A and B alone and [A] and
[B] are the MBICs of A and B when in combination.
Biofilm Cultivation in Flow Cell Chambers and Microscopy
Experiments were performed as described previously (de la Fuente-Nu´n˜ez
et al., 2014a). Biofilms were grown in BM2 glucose minimal medium for
72 hr, in the absence or presence of the desired concentration of peptides
DJK-5, DJK-6, and/or the different antibiotics tested, at 37C in flow
chambers with channel dimensions of 1 mm by 4 mm by 40 mm. Biofilm
cells were stained using the LIVE/DEAD BacLight Bacterial Viability kit
(Molecular Probes) prior to microscopy experiments. Microscopy was per-
formed using a confocal laser scanning microscope (Olympus, Fluoview
FV1000), and 3D reconstructions were generated using the Imaris software
package (Bitplane AG).
(p)ppGpp Measurement by TLC
Measurement of (p)ppGpp was performed by TLC of cells grown overnight in
modified MOPS minimal medium containing 0.4% glucose, 2 mM phosphate
(KH2PO4), and 0.2% casamino acids and treated with 500 mM SHX to induce
(p)ppGpp synthesis, in the presence or absence of peptides DJK-5 and DJK-6.
Cells were labeled with 10 mCi/ml 32P for 3 hr prior to analysis by TLC. After
chromatography, nucleotide spots were visualized by autoradiography and
quantified with a MolecularImager FX PhosphorImager and Quantity One soft-
ware (Bio-Rad).
Strains and Culture Conditions for In Vivo Experiments
P. aeruginosa PAO1was cultured in Mueller-Hinton broth (MH; Oxoid) at 37C.
E. coli OP50 was grown in TSB (Oxoid) at 37C. C. elegans N2 (glp-4; sek-1)
was propagated under standard conditions, synchronized by hypochlorite
bleaching, and cultured on nematode growth medium using E. coli OP50 as
a food source (Cooper et al., 2009; Stiernagle, 2006). AdultG.mellonella larvae
(De Poorter) were stored in wood chips at 15C in darkness prior to use. Larvae
weighing between 200 and 300 mg were used for all experiments.
C. elegans Survival Assay
The C. elegans survival assay was carried out as previously described (Brack-
man et al., 2011). In brief, synchronized worms (L4 stage) were suspended in a
medium containing 95%M9 buffer, 5% brain heart infusion broth (Oxoid), and
10 mg of cholesterol (Sigma-Aldrich) per ml. 0.5 ml of this suspension of nem-
atodes was transferred to the wells of a 24-well microtiter plate. An overnight
bacterial culture was centrifuged, resuspended in the assay medium, and
standardized to 108 CFU/ml. Next, 250 ml of this standardized suspension
was added to each well, while 250 ml of sterile medium was added to the pos-
itive control. Peptides were added to the test wells at a final concentration of
20 mg/ml. The assay plates were incubated at 25C for up to 2 days. The frac-
tion of dead worms was determined by counting the number of dead worms
and the total number of worms in each well, using a dissecting microscope.
Peptides were tested at least four times in each assay, and each assay was
repeated at least three times (n R 12). At least 100 C. elegans nematodes
were used for each condition in each assay (nR 300 nematodes/condition).
G. mellonella Survival Assay
The G. mellonella survival assay was carried out as previously described
(Brackman et al., 2011). In brief, prior to injection inG.mellonella, bacterial cells
were washed with PBS and then diluted to 104 CFU per 10 ml. A Hamilton sy-
ringe was used to inject 10 ml in the G. mellonella last left proleg. The peptides
(20 mg/10 ml) were administered by injecting 10 ml into a different proleg within
1 hr after injecting the bacteria. Two control groups were used: the first group
included uninfected larvae injected with PBS to monitor killing due to physical204 Chemistry & Biology 22, 196–205, February 19, 2015 ª2015 Elsetrauma; the second group included uninfected larvae receiving no treatment at
all. Results fromexperiments inwhich one ormore larvae in either control group
died were discarded and the experiments were repeated. To evaluate the
toxicity of the peptides, uninfected larvae were injected with peptides. Larvae
were placed in thedark at 37Candwere scored as deador alive 24 hr and48hr
post infection. Larvae were considered dead when they displayed no move-
ment in response to shaking or touch. At least 20 larvae were injected for
each treatment. For each treatment, data from at least six independent exper-
iments were combined (nR 120 G. mellonella larvae/condition).
SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables and one figure and can be found
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